While pan-JAK inhibitors such as tofacitinib and ruxolitinib have demonstrated clinical success in autoimmune diseases, selective inhibition of JAK3 remains limited because of the high sequence similarity within ATP-binding pockets of JAK1, JAK2, and JAK3 [6,7]. Here, JAK1 is linked to autoimmune disease.